Ceribell (CBLL) Capital Expenditures (2023 - 2026)

Ceribell's (CBLL) quarterly Capital Expenditures came in at -$6000.0 in Q1 2026, up 96.53% on a QoQ basis from -$173000.0 in Q4 2025.

Ceribell (CBLL) Capital Expenditures (2023 - 2026) Analysis & Trends

Ceribell (CBLL) has 4 years of Capital Expenditures data on file, last reported at -$6000.0 in Q1 2026.

Quarterly Capital Expenditures changed N/A year-over-year to -$6000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $409000.0 (up 268.47% YoY) and the FY2025 annual result came in at $415000.0, up 538.46% from the prior year.
Capital Expenditures improved to -$6000.0 in Q1 2026, from -$173000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $881000.0 in Q3 2024 to a low of -$918000.0 in Q4 2024.
A 4-year average of $105666.7 and a median of $148000.0 in 2024 frame the typical range for Capital Expenditures.
Annual changes were most pronounced in 2024 — Capital Expenditures sank 292.45% — and 2025, when it jumped 81.15%.
Tracing CBLL's Capital Expenditures over 4 years: stood at $477000.0 in 2023, then slumped by 292.45% to -$918000.0 in 2024, then jumped by 81.15% to -$173000.0 in 2025, then surged by 96.53% to -$6000.0 in 2026.
The last three Capital Expenditures figures came in at -$6000.0 (Q1 2026), -$173000.0 (Q4 2025), and $362000.0 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	497.00 Mn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	202.00 Mn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	488.00 Mn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	195.00 Mn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	66.90 Mn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	84.70 Mn
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	100.00 Mn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	-74.39 Mn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	87.50 Mn
10	Ceribell	923.42 Mn	794.16 Mn	25.94 Mn	17,000.00

Download Data